Your browser doesn't support javascript.
Minimizing the Impact of the COVID-19 Epidemic on Oncology Clinical Trials: Retrospective Study of Beijing Cancer Hospital.
Fu, Zhiying; Jiang, Min; Wang, Kun; Li, Jian.
  • Fu Z; Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China.
  • Jiang M; Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China.
  • Wang K; Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China.
  • Li J; Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China.
J Med Internet Res ; 23(3): e26799, 2021 03 02.
Article in English | MEDLINE | ID: covidwho-1085135
ABSTRACT

BACKGROUND:

In view of repeated COVID-19 outbreaks in most countries, clinical trials will continue to be conducted under outbreak prevention and control measures for the next few years. It is very significant to explore an optimal clinical trial management model during the outbreak period to provide reference and insight for other clinical trial centers worldwide.

OBJECTIVE:

The aim of this study was to explore the management strategies used to minimize the impact of the COVID-19 epidemic on oncology clinical trials.

METHODS:

We implemented a remote management model to maintain clinical trials conducted at Beijing Cancer Hospital, which realized remote project approval, remote initiation, remote visits, remote administration and remote monitoring to get through two COVID-19 outbreaks in the capital city from February to April and June to July 2020. The effectiveness of measures was evaluated as differences in rates of protocol compliance, participants lost to follow-up, participant withdrawal, disease progression, participant mortality, and detection of monitoring problems.

RESULTS:

During the late of the first outbreak, modifications were made in trial processing, participant management and quality control, which allowed the hospital to ensure the smooth conduct of 572 trials, with a protocol compliance rate of 85.24% for 3718 participants across both outbreaks. No COVID-19 infections were recorded among participants or trial staff, and no major procedural errors occurred between February and July 2020. These measures led to significantly higher rates of protocol compliance and significantly lower rates of loss to follow-up or withdrawal after the second outbreak than after the first, without affecting rates of disease progression or mortality. The hospital provided trial sponsors with a remote monitoring system in a timely manner, and 3820 trial issues were identified.

CONCLUSIONS:

When public health emergencies occur, an optimal clinical trial model combining on-site and remote management could guarantee the health care and treatment needs of clinical trial participants, in which remote management plays a key role.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cancer Care Facilities / COVID-19 / Medical Oncology Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Journal: J Med Internet Res Journal subject: Medical Informatics Year: 2021 Document Type: Article Affiliation country: 26799

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cancer Care Facilities / COVID-19 / Medical Oncology Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans / Male Country/Region as subject: Asia Language: English Journal: J Med Internet Res Journal subject: Medical Informatics Year: 2021 Document Type: Article Affiliation country: 26799